Nanobiotix
Research Nanobiotix (NBTX) on Bullrun: market cap USD 2.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNBTX
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.11B
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 2.11B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.11B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.12B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 136.05M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 342.97M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 127.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 282.09M | n/a | n/a | n/a |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nanobiotix's market cap?
Nanobiotix's market capitalization is USD 2.11B.
What does Nanobiotix do?
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A.